Monitoring the efficacy of intraarticular infliximab by musculoskeletal ultrasound and juvenile arthritis disease acitivty score (JADAS) in JIA patients – single center experience

Pediatric rheumatologists use musculoskeletal ultrasound (MSUS) in everyday practice as a simple, painless and inexpensive tool for detecting synovitis. Along with MSUS, Juvenile Arthritis Disease Activity Score (JADAS) was proven to be valid for clinical assessment. In JIA patients with mono- or oligoarthritis who are inadequately responding to conventional therapy, but do not meet criteria for biological therapy, intraarticular infliximab could be therapy of choice. Since this therapeutic option is not routinely used, there is a need for a continuous follow-up, in which MSUS and JADAS could have great value.